News Roundup: FDA-Approvals, COVID-19 Vaccine for Kids


Here’s a roundup of the latest news coverage from Drug Topics®.

Drug Topics Salary Survey 2021:

We need your opinions for the Drug Topics® 2021 Year in Review survey

Tell us about your experience with the evolving COVID-19 landscape, including regulation changes, growth in remote services, shifts in patient behavior, and emerging financial challenges. Finish the survey, and we’ll enter you into a drawing for 1 of 4 $100 Amazon gift cards.* Take the survey now (* see survey rules)

Take the survey

Prioritizing the Mental Health of Providers Across the Country

Susan Lorenz-Fisher, vice president of corporate responsibility & sustainability, AmerisourceBergen, and Erin Briggs, senior pharmacy advisor, Americares, discuss mental health awareness and resources for pharmacists to support their mental health.

Companion Diagnostic for Atezolizumab FDA-Approved for Lung Cancer Treatment

The FDA has approved the VENTANA PD-L1 assay to assist in identifying which adult patients with stage II to IIIA non–small cell lung cancer whose tumors have PD-L1 expression on 1% or more of tumor cells are eligible to receive adjuvant atezolizumab following surgery and platinum-based chemotherapy.

Pack4U Expert Interview Part 2: Medication Delivery 2.0

Shane Bishop, Pack4U's founder, is a pharmacist and entrepreneur specializing in innovative patient-care models and the use of technology to improve adherence, patient health outcomes and quality measures.

COVID-19 Vaccine FDA-Recommended for Children Ages 5-11

The US Food and Drug Administration (FDA) committee voted on whether the emergency use authorization should be extended to children aged 5 to 11 years.

Increase Medication Adherence through Patient Relationships, Part 1

Tony Makarich, PharmD and vice president of clinical services at Catalyst Health Rx, sat down with Drug Topics® to discuss the benefits for health care providers of a relationship and team-based pharmacy model.

FDA Approves Belumosudil (Rezurock) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD)

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.